Deuterated Amlexanox


Provided herein is technology relating to deuterated amiexanox and particularly, but not exclusively, to compositions comprising deuterated amiexanox, methods of producing deuterated amiexanox, and uses of deuterated amiexanox. Provided herein are deuteratecl amiexanox compounds for the treatment of obesity, insulin resistance, diabetes, and steatosis. In addition, the deuterated compounds are anti-inflammatory antiallergic immunomodulators. e.g., for the treatment of diseases associated with inflammation. The deuterium kinetic isotope effect associated with placing deuterium at the site of metabolic derivatization slows metabolic derivatization and thus increases the lifetime of the active drug in vivo.

Download PDF
Document Preview
Document History
  • Publication: Nov 6, 2014
  • Application: May 2, 2014
    WO US 2014/0036644 W
  • Priority: May 2, 2013
    US US 201361818753 P

Download Citation

Sign in to the Lens